• PDtrials - Parkinson's Disease Clinical Trials
• /Browse By Type
• /Observation (No intervention)

Official Study Title: Expanding the Phenotype of the LRRK-2 Mutation in Individuals With History of Parkinson's Disease  Parkinson's DiseaseA chronic, slowly progressive disease of the nervous system characterized by the combination of tremor, rigidity, bradykinesia and stooped posture, among other symptoms. and Their Relatives: a Prospective Study
Sponsor: National Institute of Neurological Disorders and Stroke  National Institute of Neurological Disorders and Stroke (NINDS)A branch of the National Institutes of Health whose research concentrates on the brain and conditions that result in brain function irregularities. The NINDS funds much of the research on Parkinson's disease. Internet address: http://www.ninds.nih.gov (NINDS)
Clinicaltrials.gov ID: NCT00467090
Study ID: 070137; 07-N-0137

Summary

Parkinson's disease (PD) is a neurological condition that was originally thought to develop from environmental factors. More recently, genetic  GeneticReferring to a condition that is caused by a person's genes (heredity). factors have been implicated. This study will examine the phenotypic presentation of people with PD due to a specific defect in a gene  GeneUnits of heredity that are made of DNA and contained in every cell. They produce proteins that control biological development and function. (LRRK-2). This defect is found in some people with PD. (The term "phenotypic" refers to a person's visible or otherwise measurable physical or biochemical characteristics, as determined by his/her genetic makeup and environmental influences.) In addition, family members whose genetic status is unknown will also be studied to help researchers develop a pre-clinical  Pre-clinicalTesting of investigational drugs or treatments in the laboratory or in animals before trials in humans are carried out. description of PD progression.

Study Phase

Not Specified
What is a study phase?

Symptoms Addressed: Study does not address symptoms

Study does not address symptoms

Time Commitment

• Contact trial organizers

Eligibility

• Minimum Age: 18
• Gender(s) Accepted: Either
• Study is enrolling non-PD participants

Inclusion Criteria

• Persons with a diagnosis of PD with a known LRRK-2 gene mutation, OR
• First degree relatives without a diagnosis of PD, with a family history suggestive of inherited PD due to LRRK-2 gene mutations.

Exclusion Criteria

• Persons with a history of severe head injury, encephalitis, chronic use of drugs that cause parkinsonism or a clinical  ClinicalDealing with or based on observation and treatment of people, as opposed to basic science carried out in the laboratory or in animals. history of strokes.
• For the MRI: women who are pregnant.
• For the MRI: persons with pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips, metallic prostheses, permanent eyeliner, implanted delivery pump, or shrapnel fragments.

Enrollment

Expected Enrollment: 200 (US)
Date Enrollment Began: Apr 01 2007
Last Updated Date: Jun 11 2007
Trial Post Date: Jun 11 2007
Website: http://clinicaltrials.gov/ct/show/NCT00467090?order=1

Primary Contacts and Locations

Maryland

• Patient Recruitment and Public Liaison Office
  National Institutes of Health  National Institutes of Health (NIH)The National Institutes of Health, a part of the U.S. Department of Health and Human Services, is the primary Federal agency for conducting and supporting medical research. Headquartered in Bethesda Maryland, it is composed of 27 Institutes and Centers and provides leadership and financial support to researchers in every state and throughout the world. Internet address: http://www.nih.gov. Clinical Center
  prpl@mail.cc.nih.gov
  Phone: (800) 411-1222
  9000 Rockville Pike
  Bethesda, MD 20892
  USA